share_log

T2 Biosystems | 8-K: Current report

T2 Biosystems | 8-K: Current report

T2 Biosystems | 8-K:重大事件
美股SEC公告 ·  2024/11/08 22:35

Moomoo AI 已提取核心信息

On November 7, 2024, T2 Biosystems received a delisting determination from Nasdaq as the company's market value of listed securities fell below the minimum requirement of $35 million for 30 consecutive trading days. Under the terms of the previously imposed Mandatory Panel Monitor, Nasdaq did not grant a grace period.The company plans to request a hearing before the Nasdaq Hearings Panel and pay a $20,000 non-refundable fee, which will stay any delisting action pending the Panel's decision. The company's common stock will continue trading on Nasdaq during this process.However, there is no guarantee that the Panel will grant T2 Biosystems' request for continued listing or that the company will meet all applicable listing criteria within any extension period that may be granted.
On November 7, 2024, T2 Biosystems received a delisting determination from Nasdaq as the company's market value of listed securities fell below the minimum requirement of $35 million for 30 consecutive trading days. Under the terms of the previously imposed Mandatory Panel Monitor, Nasdaq did not grant a grace period.The company plans to request a hearing before the Nasdaq Hearings Panel and pay a $20,000 non-refundable fee, which will stay any delisting action pending the Panel's decision. The company's common stock will continue trading on Nasdaq during this process.However, there is no guarantee that the Panel will grant T2 Biosystems' request for continued listing or that the company will meet all applicable listing criteria within any extension period that may be granted.
2024年11月7日,T2 Biosystems收到了纳斯达克的退市通知,因为该公司的上市证券市场价值连续30个交易日低于3500万美元的最低要求。根据之前施加的强制性小组监察条款,纳斯达克不允许宽限期。该公司计划请求纳斯达克听证小组进行听证,并支付20,000美元不可退还的费用,这将在小组决定之前暂停任何退市行动。在此过程中,该公司的普通股将继续在纳斯达克交易。然而,并不能保证小组会批准T2 Biosystems的继续上市请求,也不能保证公司会在赢得任何可能的延长期内满足所有适用的上市标准。
2024年11月7日,T2 Biosystems收到了纳斯达克的退市通知,因为该公司的上市证券市场价值连续30个交易日低于3500万美元的最低要求。根据之前施加的强制性小组监察条款,纳斯达克不允许宽限期。该公司计划请求纳斯达克听证小组进行听证,并支付20,000美元不可退还的费用,这将在小组决定之前暂停任何退市行动。在此过程中,该公司的普通股将继续在纳斯达克交易。然而,并不能保证小组会批准T2 Biosystems的继续上市请求,也不能保证公司会在赢得任何可能的延长期内满足所有适用的上市标准。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息